148 related articles for article (PubMed ID: 11587490)
1. A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.
Grange S; Holford NH; Guentert TW
Pharm Res; 2001 Aug; 18(8):1174-84. PubMed ID: 11587490
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
4. In vivo microdialysis to determine the relative pharmacokinetics of drugs.
Nakashima M; Zhao MF; Nakashima MN; Sakurai M; Sasaki H; Matsuyama K; Ichikawa M
Biol Pharm Bull; 1996 Jul; 19(7):988-94. PubMed ID: 8839975
[TBL] [Abstract][Full Text] [Related]
5. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics.
Dingemanse J; Kleinbloesem CH; Zürcher G; Wood ND; Crevoisier C
Br J Clin Pharmacol; 1997 Jul; 44(1):41-8. PubMed ID: 9241095
[TBL] [Abstract][Full Text] [Related]
7. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA
J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
10. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.
Acquas E; Carboni E; de Ree RH; Da Prada M; Di Chiara G
J Neurochem; 1992 Jul; 59(1):326-30. PubMed ID: 1613509
[TBL] [Abstract][Full Text] [Related]
11. Central action of benserazide after COMT inhibition demonstrated in vivo by PET.
Tedroff J; Hartvig P; Bjurling P; Andersson Y; Antoni G; Långström B
J Neural Transm Gen Sect; 1991; 85(1):11-7. PubMed ID: 1867835
[TBL] [Abstract][Full Text] [Related]
12. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
13. Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
Tayarani-Binazir KA; Jackson MJ; Strang I; Jairaj M; Rose S; Jenner P
Behav Pharmacol; 2012 Apr; 23(2):126-33. PubMed ID: 22236652
[TBL] [Abstract][Full Text] [Related]
14. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
15. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
16. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
Silveira P; Vaz-da-Silva M; Almeida L; Maia J; Falcão A; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):603-9. PubMed ID: 14517707
[TBL] [Abstract][Full Text] [Related]
18. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
Pellegrini C; Antonioli L; Colucci R; Tirotta E; Gentile D; Ippolito C; Segnani C; Levandis G; Cerri S; Blandini F; Barocelli E; Ballabeni V; Bernardini N; Blandizzi C; Fornai M
Neuropharmacology; 2017 Sep; 123():22-33. PubMed ID: 28526609
[TBL] [Abstract][Full Text] [Related]
19. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
[TBL] [Abstract][Full Text] [Related]
20. The pharmacology of Parkinson's disease: basic aspects and recent advances.
Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
